Impact of glycemia and insulin treatment in fatal outcome of severe fever with thrombocytopenia syndrome.
Int J Infect Dis
; 119: 24-31, 2022 Jun.
Article
in English
| MEDLINE | ID: covidwho-2069113
ABSTRACT
BACKGROUND:
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease with a high fatality rate. How the glucose level might affect the clinical outcome remains obscure.METHODS:
A multicenter study was performed in 2 hospitals from 2011 to 2021. Patients with SFTS and acute hyperglycemia (admission fasting plasma glucose [FPG] ≥7 mmol/L), postadmission hyperglycemia (admission FPG <7 mmol/L but FPG ≥7 mmol/L after admission), and euglycemia (FPG <7 mmol/L throughout hospitalization) were compared for their clinical progress and outcomes.RESULTS:
A total of 3225 patients were included in this study, 37.9% of whom developed acute hyperglycemia and 7.6% postadmission hyperglycemia. The presence of acute hyperglycemia, with or without known diabetes, was associated with increased risk of death (odds ratio [OR] 1.63; 95% confidence interval [CI] 1.29-2.05) compared with euglycemia. This effect, however, was only determined in female patients (OR 2.15; 95% CI 1.54-2.93). Insulin treatment of patients with SFTS and acute hyperglycemia without previous diabetes was associated with significantly increased mortality (OR 1.58; 95% CI 1.16-2.16).CONCLUSION:
Acute hyperglycemia can act as a strong predictor of SFTS-related death in female patients. Insulin treatment of hyperglycemia in patients with SFTS without pre-existing diabetes has adverse effects.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
Insulins
/
Severe Fever with Thrombocytopenia Syndrome
/
Hyperglycemia
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Female
/
Humans
Language:
English
Journal:
Int J Infect Dis
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS